Day: March 8, 2022

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA TORONTO, March 08, 2022 (GLOBE NEWSWIRE) — Sintana Energy Inc. (TSXV: SEI) (the “Company” or “Sintana”) is pleased to announce that it has closed its previously announced marketed public offering (the “Offering”) conducted by Echelon Capital Markets (the “Agent”) as lead agent and sole bookrunner, pursuant to which it issued an aggregate of 88,550,000 units (the “Units”) of the Company, at a price of $0.15 per Unit, to raise aggregate gross proceeds of $13,282,500 (including full exercise of an over-allotment option). The Offering was effected pursuant to a final short form prospectus of the Company dated February 24, 2022 (the “Final Prospectus”), and was upsized from the originally announced maximum base offering of $10 million...

Irreversible covalent menin inhibitor, BMF-219, exhibited high potency and complete growth inhibition in high-grade B-cell lymphoma and multiple myeloma (MM) preclinical patient derived ex vivo models BMF-219 demonstrated high potency in various KRAS-mutant cell lines, as well as potential advantages over the KRAS-targeted inhibitor sotorasib in multiple cell lines BMF-219 showed strong potency in ex vivo preclinical models of colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic cancerREDWOOD CITY, Calif., March 08, 2022 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic...

Context to host webinar with AACR presenters on Wednesday, April 13, 2022, at 11 a.m. ET PHILADELPHIA, March 08, 2022 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA. “Context is committed to advancing new therapeutics for female cancers and we are proud to have our compounds showcased at the upcoming AACR Annual Meeting,” said Martin Lehr, CEO of Context Therapeutics. “We look forward to the presentations from investigators...

Poster presentations to highlight data from ongoing studies of the company’s lead Pan-RAF kinase inhibitor program, KIN-2787 SAN FRANCISCO and SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) — Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced abstracts highlighting the company’s lead RAF kinase inhibitor program, KIN-2787, have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, to be held April 8-13, in New Orleans, Louisiana. Abstracts accepted for poster presentation include:Occurrence of BRAF class II and III alterations is common across solid tumors and is associated with inferior clinical outcomes...

Not for dissemination in the United States of America. VANCOUVER, British Columbia, March 08, 2022 (GLOBE NEWSWIRE) — Loan Agreement Premier Diversified Holdings Inc. (“Premier” or the “Company“) (TSXV: PDH) announces that it has entered into a loan agreement with MPIC Fund I, LP (“MPIC“) for a secured loan in the principal amount of up to USD$120,000 (the “Loan“). The Loan matures on February 10, 2023 and bears interest at a rate of 6% per annum. The Loan is secured with all of the present and after-acquired property of the Company and ranks equally in priority with all of the loans previously made to the Company by MPIC. The Loan will be used for working capital (including for Premier’s partially owned subsidiaries, Purposely Platform Inc. and MyCare MedTech Inc.) and may be used...

Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea’s neoantigen-targeted peripheral T cell therapy for solid tumors The PLANET manufacturing process reliably generates abundant, high-quality neoantigen-specific T cells Preclinical data indicate that Inhibigens™ accelerate tumor growth in animal models of pancreatic cancer and melanoma CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will present clinical, preclinical, and manufacturing data at next month’s American Association for Cancer Research (AACR) Annual Meeting 2022 to be held from April 8-13 in New Orleans. The findings include late-breaking clinical data from the TiTAN™ clinical trial for the neoantigen-targeted...

HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) — Targa Resources Corp. (NYSE: TRGP) (“Targa” or the “Company”) announced today that representatives from the Company will participate in investor meetings via video conference at the Evercore ISI Elite Energy & Materials Summit on Wednesday, March 9, 2022. A copy of the slides used for the conference meetings will be available in the Investors section of the Company’s website at www.targaresources.com, or by going to https://www.targaresources.com/investors/events. About Targa Resources Corp. Targa Resources Corp. is a leading provider of midstream services and is one of the largest independent midstream infrastructure companies in North America. The Company owns, operates, acquires and develops a diversified portfolio of complementary midstream infrastructure...